YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Apitegromab MAA resubmission includes alternate fill-finish facility in place of Catalent Indiana LLC (part of Novo Nordisk), in alignment with guidance from EMA Alternate fill-finish facility in MAA is the same site that supported Septemb…
Eli Lilly and Company's LLY stock has declined around 2.3% in the past three months despite very strong underlying business momentum. The main issue is expectations and valuation rather than a deterioration in fundamentals. Investors have…
During the October 1 lightning round of Mad Money, a caller said they owned both Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Company (NYSE:LLY). After contrasting their share-price performance, they asked which offered better upside over…
In the latest trading session, Novo Nordisk (NVO) closed at $38.26, marking a +1.95% move from the previous day. This change outpaced the S&P 500's 0.22% loss on the day. Elsewhere, the Dow saw a downswing of 0.66%, while the tech-heavy Na…
A Dutch court rules in favor of Halozyme Therapeutics, barring Merck from selling subcutaneous Keytruda in eight European markets. Continue Reading
Viking Therapeutics VKTX announced the initiation of a clinical study evaluating oral maintenance dosing of its lead obesity candidate, VK2735. The study, which is designed to enroll approximately 195 adults with obesity, will evaluate whe…
European equities traded in the US as American depositary receipts fell late Wednesday morning with PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Novo Nordisk has seen a sharp reset in its share price over the past few years, and that shift is forcing investors to ask whether the current valuation is still supported by its earnings power. With headline-making data for semaglutide ac…
Novo NVO has an opportunity to extract greater value from semaglutide by expanding its use beyond traditional diabetes, obesity and cardiovascular indications. This strategy is increasingly relevant as the company faces intense competition…
European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Shares of Agios Pharmaceuticals AGIO have declined 29% over the past three months despite strong growth in mitapivat sales in the second quarter of 2026. The decline largely reflects setbacks to tebapivat, a key pipeline candidate, which h…
Shares of Viking Therapeutics VKTX have lost about 16% over the past month, despite the positive results from a maintenance dosing study evaluating its lead obesity candidate, VK2735. The recent weakness appears to be driven largely by inv…
Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the past month, shares of this drug…
DelveInsight Business Research LLP The type 2 diabetes market is expected to witness steady growth, driven by the rising global prevalence of diabetes, increasing rates of obesity and sedentary lifestyles, and growing awareness of early di…
Four sessions across two days focusing on key drug discovery and development application areas oforgan-on-a-chip technologies Expert-led presentations and panel discussions featuring leaders across research, regulatory and industry, includ…
Johnson & Johnson JNJ and Pfizer PFE are two major healthcare companies with significant exposure to oncology. J&J also has a diversified portfolio spanning immunology, neuroscience, cardiovascular and metabolic diseases, pulmonary hyperte…
Novo's NVO denecimig biologics license application (BLA) review in the United States is facing an extended timeline after the FDA informed the company that the review of the investigational therapy for haemophilia A remains ongoing. The FD…
In the past, Novo Nordisk A/S (NYSE:NVO) has been a dominant player in diabetes and obesity treatments, with Ozempic and Wegovy driving a significant portion of the company's recent growth. Those drugs transformed the company into one of t…
Novo Nordisk A/S Bagsværd, Denmark, 5 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) an…
Wall Street closed in the green on Friday after the September nonfarm payrolls report came in cooler than economists expected. The blue-chip Dow ended up 0.5%, the benchmark S&P 500 gained 0.7%, and the tech-focused Nasdaq Composite advanc…
[Blood sample for hemophilia test, inherited genetic bleeding disorder] Md Saiful Islam Khan/iStock via Getty Images * The USA FDA has extended its review of Novo Nordisk's (NVO [https://seekingalpha.com/symbol/NVO]) BLA seeking approval o…
Novo Nordisk A/S The US Food and Drug Administration (FDA) has informed Novo that the BLA review of denecimig for the treatment of haemophilia A is still ongoing. The FDA has not communicated a new timeline for regulatory action on the BLA…
Dexcom DXCM recently released its 2026 "State of Type 2 Report: Global Access and Attitudes to Diabetes Technology" ahead of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD). The report highlights signif…
Agios Pharmaceuticals AGIO is entering an important phase of its growth story as its lead therapy, mitapivat, expands across multiple blood disorders. The drug is marketed as Pyrukynd for pyruvate kinase (PK) deficiency and as Aqvesme for…
Eli Lilly and Company LLY presented new efficacy data from studies of its marketed and investigational metabolic medicines at the annual European Association for the Study of Diabetes (EASD) conference. Foundayo (orforglipron), a once-dail…
Eli Lilly doubles down on its pipeline with new data for weight-loss pill Foundayo and next-generation combo drug EloraTZP. Continue Reading
Novo's NVO oral Wegovy (semaglutide) is showing real-world weight-loss benefits among adults with overweight or obesity who switched from injectable GLP-1 therapies. Data from the OCTANE study found that people moving from Eli Lilly's LLY…
The 2026 European Association for the Study of Diabetes ("EASD") annual meeting in Milan has become the stage for a fierce data duel between Eli Lilly LLY and Novo Nordisk NVO. Both pharma giants unveiled new clinical evidence to bolster t…
Novo Nordisk A/S Novo reports analysis from STEP UP trial sub-population in which most participants with elevated liver fat achieved improved liver health after 72 weeks of Wegovy®(injectable semaglutide 7.2 and 2.4 mg) treatment. 9 in 10…
[Doctor doing research in lab during COVID-19] Morsa Images * An experimental weight-loss drug being developed by Regeneron (REGN [https://seekingalpha.com/symbol/REGN]) used in combination with Novo Nordisk's (NVO [https://seekingalpha.co…
Novo NVO announced new real-world data from the COMPETE SWITCH Cardiovascular (CV) study comparing treatment strategies in adults with type II diabetes (T2D) who were already receiving a 1-mg dose of Ozempic (semaglutide) injection. The an…
[Cantor And John Thune Hold Press Conference On Economy] Alex Wong/Getty Images News * The Pharmaceutical Research and Manufacturers of America (PhRMA) has selected former Republican House Majority Leader Eric Cantor as its next CEO and pr…
Investing.com -- Shares of Eli Lilly and Company (NYSE: LLY) climbed as much as 2.6% before settling up 0.5% after the pharmaceutical giant reported highly positive Phase 2b trial results for its new obesity and type 2 diabetes drug combin…
Novo Nordisk A/S In a year-long functional magnetic resonance imaging (fMRI) study - a non-invasive method to measure brain activity during specific tasks - CagriSema changed how the brain reacted to tempting, high-calorie foods in areas l…
Novo NVO is expanding its external innovation strategy with the latest license agreement with Hengrui Pharma for HRS-1596, a phase I-ready GLP-1/GIP dual receptor agonist with potential for once-weekly oral dosing. Under the deal, Novo gai…
Novo Nordisk (NVO) closed at $38.31 in the latest trading session, marking a -1.03% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.17%. Elsewhere, the Dow saw a downswing of 0.26%, while the tech…